Complications of arterial closure devices.
As of July 2000, there were 4 closure devices with Food and Drug Administration (FDA) approval. The devices are successfully deployed in 89% to 98% of cases, and the complication rates are comparable to those seen with manual compression. Minor access site complications are defined as bleeding not requiring transfusion or surgical repair, hematoma (<5 cm), and pain at the puncture site. Major complications include hematoma (>5 cm), bleeding at the site requiring transfusion, pseudoaneurysm, arteriovenous fistula, retroperitoneal hemorrhage, plug embolization, groin infection, and death.
Lewis-Carey
Mary Beth
MB
University of New Mexico, Albuquerque, NM 87131-5336, USA.
Kee
Stephen T
ST
D000925:Anticoagulants / Q000627:therapeutic use; D001157:Arterial Occlusive Diseases / Q000209:etiology; D006406:Hematoma / Q000209:etiology; D006488:Hemostasis, Surgical / Q000009:adverse effects*; D006489:Hemostatic Techniques / Q000009:adverse effects / Q000295:instrumentation*; D006801:Humans; D007239:Infections / Q000209:etiology; D011677:Punctures; D013536:Suture Techniques / Q000295:instrumentation*; D014481:United States; D014486:United States Food and Drug Administration
D000925:Anticoagulants